Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00731185
Other study ID # P03218
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date September 1, 2003
Est. completion date September 1, 2005

Study information

Verified date February 2022
Source Organon and Co
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study was conducted to evaluate the effectiveness of mometasone nasal spray in preventing polyp relapse/symptom worsening in patients after surgical treatment of nasal polyps. Patients who met Screening eligibility underwent endoscopic sino-nasal surgery (FESS) on visit 2. Mometasone nasal spray or placebo was started about 2 weeks after surgery and continued for up to 24 weeks or until relapse.


Recruitment information / eligibility

Status Completed
Enrollment 162
Est. completion date September 1, 2005
Est. primary completion date September 1, 2005
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - At least 18 years of age - Bilateral nasal polyps - Fulfill criteria for polypectomy (be indicated for surgical - FESS - treatment) Exclusion Criteria: - Polypectomy within the last 6 months - Unhealed nasal surgery/trauma - >5 previous polypectomies - Female of childbearing age who is pregnant, lactating, or not using active contraceptive methods - Nasal infection - Pulmonary tuberculosis - Cystic fibrosis, glaucoma, clinically significant cardiovascular, pulmonary, renal, hepatic, metabolic, hematological, or neurological disease - Immunocompromised - Rhinitis medicamentosa (rebound congestion following misuse of nasal decongestants) - Known hereditary mucociliary dysfunction - Significant nasal structure abnormalities - Asthmatic attack within the past 30 days - Asthmatic patients requiring >1000 mcg beclomethasone or equivalent - Asthmatic patients not stable on corticosteroid therapy

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Mometasone Furoate Nasal Spray
MFNS 200 mcg (2 sprays of 50 mcg in each nostril) once daily in the morning for up to 24 weeks or until relapse
Placebo


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Organon and Co

Outcome

Type Measure Description Time frame Safety issue
Primary Time to relapse in polyp score after surgery Assessment for relapse was performed at every study visit (up to 24 weeks of treatment)
Secondary Signs and symptom scores All study visits (up to 24 weeks of treatment)
Secondary Quality of life, peak nasal inspiratory flow, olfaction threshold Measured starting 1 week after treatment up to 24 weeks of treatment
Secondary Adverse events Throughout the whole study after the Screening period.
See also
  Status Clinical Trial Phase
Withdrawn NCT02071667 - Association of Periostin Levels and Chronic Sinusitis N/A
Completed NCT01623310 - 12-Month OL Intranasal Fluticasone Propionate BID Using OptiNose Device Phase 3
Completed NCT02024659 - Effects and Safety of Budesonide Inhalation Suspension Via Transnasal Nebulization in Nasal Polyps Phase 2/Phase 3
Completed NCT00215787 - Investigation of the Association Between Nasal Polyposis and Extraesophageal Reflux Disease N/A
Completed NCT04996576 - Infrazygomatic Versus Intranasal Injection Sphinopalatine Ganglion Blockade Effect on Surgical Field in FESS N/A
Recruiting NCT03963648 - NO Measurements in Screening for Asthma and OSA, in Patients With CRSwNP N/A
Recruiting NCT05094570 - Interleukin-4Ra Blockade by Dupilumab Decreases Staphylococcus Colonization and Increases Microbial Diversity in CRSwNP Phase 4
Recruiting NCT05009758 - Moving Towards Precision Medicine in United Airways Disease: Unraveling Inflammatory Patterns in Asthmatic Patients With or Without Nasal Polyps N/A
Active, not recruiting NCT03943121 - The Effects of Steroid-eluting Stent Implant for the Treatment of Eosinophilic Chronic Rhinosinusitis With Nasal Polyps N/A
Active, not recruiting NCT03704415 - Aggravated Airway Inflammation: Research on Genomics and Optimal Operative Treatment (AirGOs Operative) N/A
Not yet recruiting NCT06070311 - Wound Healing After Endoscopic Sinus Surgery N/A
Completed NCT02879929 - Development and Validity of the DyNaChron Questionnaire for Chronic Nasal Dysfunction N/A
Recruiting NCT05672030 - Role of IL-5R Signaling in Non-eosinophil Upper Airway Cells in CRSwNP
Suspended NCT04261582 - Genetics and Genomics of Aspirin Exacerbated Respiratory Disease (AERD)
Recruiting NCT05063981 - Treatment With Mepolizumab on Patients With Severe Refractory Eosinophilic Asthma With or Without CRSwNP.
Completed NCT05180357 - RANS. Study in Patients With Severe Eosinophilic Asthma and Nasal Polyps.
Completed NCT00788463 - A Comparison of Beclomethasone Aqueous Spray and Aerosol Delivery Systems in Nasal Polyps Phase 2
Completed NCT01198912 - Influence of Oral Doxycycline on Wound Healing After Endonasal Endoscopic Sinus Surgery for Chronic Rhinosinusitis With and Without Nasal Polyposis: a Double-blind Randomized Placebo-controlled Trial Phase 2
Completed NCT03280537 - A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitus With Nasal Polyps Phase 3
Completed NCT00440219 - The Effect of Preoperative Oral Prednisone on the Operative Field During Nasal Polypectomy. Phase 3